Biotech Firm Medera Set to Go Public in $623M SPAC Deal
Medera is focused on eradicating cardiovascular diseases with a range of gene- and cell-based approaches in combination with bioengineered human-based technology.
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
